MCED Test Performance in Obese Individuals
This abstract evaluates a multi-cancer early detection (MCED) blood test specifically designed for individuals with obesity, a group at higher risk for several cancers often without standard screening. The study investigated the test’s ability to accurately detect cancer and identify the tissue of origin using a two-step methylation profiling method. Results showed the test had a high positive predictive value (PPV) and reasonable sensitivity, […]
The role of GLP-1 receptor agonists in the management of obesity
As Australia faces a turning point in obesity management, researchers from Monash University have contributed new insights into the rapidly evolving use of glucagon-like peptide-1 receptor agonists (GLP-1 RAs) such as Ozempic in the Australian health care system.
The Dark And Light Side Of Ozempic: Here’s What Experts Say About The Popular Diet Medicine
Not that long ago, it was found that 1 in 8 adults in the United States has taken Ozempic or a similar medicine. While some of them take it for their diabetes, others, as you probably know, take it as a way to lose weight. This usage has become so common that some have dubbed […]
Veru: Saving Muscle Mass Amidst The GLP-1 Drug Boom
Post Content
Study compares Zepbound and Wegovy for weight loss in direct comparison
Weight-loss medications continue to grow in popularity as an anti-obesity tool — but are some more effective than others? The question was explored in a new study published this month in The New England Journal of Medicine. Researchers compared the safety and efficacy of tirzepatide (brand name Zepbound) and semaglutide (brand name Wegovy) in a […]